What is Chemotherapy-Induced Nausea and Vomiting (CINV) Market?
Chemotherapy-induced nausea and vomiting (CINV) is one of the most frequently reported adverse events in patients receiving chemotherapy. If nausea and vomiting become severe, dehydration, metabolic disturbances, malnutrition, or aspiration pneumonia may occur. Treatments that prevent or reduce CINV are therefore an integrated part of the supportive care of cancer patients. According to Cancer Research UK, cancer caused almost 9.6 million deaths worldwide in 2018.
Highlights from Chemotherapy-Induced Nausea and Vomiting (CINV) Market Study
|Unit||Value (USD Million)|
|Key Companies Profiled||Merck & Co. (United States), Eisai (Japan), Kyowa Hakko Kirin Co. Ltd. (Japan), Helsinn Holding (Switzerland), Pfizer Inc. (United States), Mundipharma International (United Kingdom), Qilu Pharma (China), Teva Pharmaceutical Industries (Israel), Novartis (Switzerland) and Heron Therapeutics (United States)|
Companies can differentiate themselves by investing in research and development to create innovative and more effective CINV treatments. This could involve developing new drug formulations, exploring novel mechanisms of action, or improving the delivery methods of existing drugs. Additionally, the players explore new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Research Analyst at AMA predicts that United States Players will contribute to the maximum growth of Global Chemotherapy-Induced Nausea and Vomiting (CINV) market throughout the forecasted period. Merck & Co. (United States), Eisai (Japan), Kyowa Hakko Kirin Co. Ltd. (Japan), Helsinn Holding (Switzerland), Pfizer Inc. (United States), Mundipharma International (United Kingdom), Qilu Pharma (China), Teva Pharmaceutical Industries (Israel), Novartis (Switzerland) and Heron Therapeutics (United States) are some of the key players profiled in the study. Additionally, the Players which are also part of the research are Roche Holding AG (Switzerland) and Mylan (United States).
Chemotherapy-Induced Nausea and Vomiting (CINV) Market Segmentation:
|Application / End User||Hospitals, Ambulatory Surgical Centers and Diagnostic Centers|
|Type||CINV and PONV|
|Patient Pool Type||Aloxi, Kytril,Emend,Netupitant-Palonosetron,Others|
|Route of Administration||Oral,Intravenous|
On the basis of geography, the market of Chemotherapy-Induced Nausea and Vomiting (CINV) has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.
The Development and Launch of Novel Drug Delivery Methods for CINV Drugs and High Demand for Combination Therapy and Increasing Preference for Pressure Point Therapy
Market Growth Drivers:
Increase in adoption of chemotherapeutic drugs, Rise in the Incidence of Cancer Cases and Growing Healthcare Expenditure and Accelerating Economic Growth
Stringent Regulations and High Treatment Cost of Chemotherapy-Induced Nausea and Vomiting (CINV)
High Price of CINV Drugs
Growth in the Number of Patients Undergoing Chemotherapy Drugs Treatment Across the World and Increasing Pharmaceutical R&D Spending
Key Target Audience
Chemotherapy-Induced Nausea and Vomiting (CINV) Treatment, Chemotherapy-Induced Nausea and Vomiting (CINV) Association, Testing Laboratories, Research and Development Institutes, Financial Institutes and Investors, Regulatory Bodies and Others
Market Leaders & Development Strategies
In August 2016, Heron Therapeutics received U.S. FDA approval for SUSTOL, an extended-release injection of granisetron for the prevention of CINV.
In the United States, the Food and Drug Administration (FDA) is the regulatory authority responsible for approving and monitoring drugs for various conditions, including CINV. The FDA evaluates the safety and efficacy of drugs through a rigorous review process before granting approval for their use. They also continue to monitor drugs after approval to ensure their continued safety and effectiveness.